Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

BACKGROUND: Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international, open-label, randomised controlled trial—uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (doceta...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Nicholas D, Sydes, Matthew R, Mason, Malcolm D, Clarke, Noel W, Anderson, John, Dearnaley, David P, Dwyer, John, Jovic, Gordana, Ritchie, Alastair WS, Russell, J Martin, Sanders, Karen, Thalmann, George N, Bertelli, Gianfilippo, Birtle, Alison J, O'Sullivan, Joe M, Protheroe, Andrew, Sheehan, Denise, Srihari, Narayanan, Parmar, Mahesh KB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398767/
https://www.ncbi.nlm.nih.gov/pubmed/22452894
http://dx.doi.org/10.1016/S1470-2045(12)70088-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398767/
https://www.ncbi.nlm.nih.gov/pubmed/22452894
http://dx.doi.org/10.1016/S1470-2045(12)70088-8

Ejemplares similares